Investment opportunities that have the potential to change the lives of billions of people rarely come along.
Our vision is for every woman to be empowered with an effective, private, and comfortable cervical self-screening option, in order to increase global accessibility and cervical cancer survivability rates worldwide.
Our Mission is to develop user friendly self-testing methodologies for the most common gynecological tests and screens, providing critical technological and user experience upgrades, bringing the OB-GYN standard-of-care model into the 21st century.
The first phase of clinical trials is expected to begin in early 2022. Our community is expanding day by day, and we plan to launch a monthly newsletter, virtual and physical events for our professional network partners, and regular development progress reports for our potential investors soon.
If you’re interested in learning more about PapEasy’s investment opportunities, fill out the online form on this page, and one of our partners will contact you to set up an introduction meeting to go over the specifics in more details.